In September, BioNTech wants to launch new vaccines – adapted to the rampant Covid 19 variants. Selling in single doses is intended to simplify vaccination. US manufacturers are planning to do the same.
According to a media report, the Mainz-based vaccine manufacturer BioNTech wants to deliver its adapted vaccines against Covid-19 in September as announced – subject to official approval. The group announced this to the “Ärzte Zeitung”. The vaccines adapted to the new corona variants are therefore about to be delivered. They should be easier to handle, as the “Ärzte Zeitung” writes.
BioNTech and Pfizer have adapted their vaccine to the omicron variant XBB.1.5. The EG.5 variant currently circulating in Germany – known under the name Eris – also descends from XBB.
The US company Moderna told the newspaper that it would launch the mRNA vaccine “in time for the fall vaccination season” and subject to approval. This vaccine is also tailored to the omicron variant XBB.
“Just in Time for Vaccination Season”
Both manufacturers want to deliver the vaccines in so-called single-dose containers for the first time. This makes it easier for doctors to vaccinate them. Until now, vaccines have come in multi-dose vials with a limited shelf life once opened.
According to the report, the US company Novavax also wants to deliver a vaccine adapted to the XBB variant in autumn. The company told the newspaper it also plans to transition to smaller dosage forms, including single-dose vials.
Recommendation for over 60 year olds
The chairman of the Bavarian Association of General Practitioners, Wolfgang Ritter, recommended that all people over the age of 60 and other members of risk groups make use of the new vaccination options.
“Ultimately, the vulnerable groups and patients over 60 should refresh their vaccinations,” said Ritter Bavarian radio. He also referred to the renewed increase in the number of corona infections. In principle, this is not a cause for concern.